Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8671542 | 0.84 | BLM (0.46) | DUT | |
| SCHEMBL27383375 | 0.79 | DUT (0.33) | DUT | |
| SCHEMBL14965578 | 0.79 | BLM (0.41) | — | |
| SCHEMBL24614981 | 0.76 | BLM (0.32) | DUT | |
| SCHEMBL3321433 | 0.76 | DUT (0.33) | DUT | |
| SCHEMBL14965387 | 0.75 | KDM4E (0.30) | — | |
| SCHEMBL28516260 | 0.74 | DUT (0.39) | DUT | |
| SCHEMBL27383371 | 0.74 | — | — | |
| SCHEMBL15176109 | 0.74 | — | — | |
| SCHEMBL1671907 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040029897-A1 | Frangible compounds for pathogen inactivation | CERUS CORPORATION (US) | 2004-02-12 | — | — | US | disclosed |
| EP-1364944-A1 | Frangible Compounds for Pathogen Inactivation | Cerus Corporation (US) | 2003-11-26 | — | — | EP | disclosed |
| US-6514987-B1 | Useful for inactivating pathogens in a material, such as a blood product, and then degrades to breakdown products | CERUS CORPORATION | 2003-02-04 | — | — | US | disclosed |
| EP-1021414-A1 | FRANGIBLE COMPOUNDS FOR PATHOGEN INACTIVATION | Cerus Corporation (US) | 2000-07-26 | — | — | EP | disclosed |
| US-6093725-A | A BINDER FOR DEACTIVATING PATHOGENS IN A BLOOD SAMPLE TO BIND NUCLEIC ACID BY COVALENT LINKAGE | CERUS CORPORATION (US) | 2000-07-25 | — | — | US | disclosed |
| CN-1248245-A | Friable compounds for pathogen inactivation | CERUS CORP (US) | 2000-03-22 | — | — | CN | disclosed |
| WO-1998030545-A9 | FRANGIBLE COMPOUNDS FOR PATHOGEN INACTIVATION | — | 1998-12-30 | — | — | WO | disclosed |
| WO-1998030545-A1 | FRANGIBLE COMPOUNDS FOR PATHOGEN INACTIVATION | CERUS CORPORATION (US) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029897-A1 | Frangible compounds for pathogen inactivation | TIAL1, PRF1, DNASE1 | DUT 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.